Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeTPSTTempest Therapeutics$7.16+0.6%$9.10$5.33▼$49.27$25.18M-2.3470,491 shs1,641 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceTPSTTempest Therapeutics-3.13%-9.89%-25.89%-42.12%-84.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationTPSTTempest Therapeutics2.0125 of 5 stars3.35.00.00.01.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceTPSTTempest Therapeutics 2.50Moderate Buy$30.00319.29% UpsideCurrent Analyst Ratings BreakdownLatest TPST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$16.00 ➝ $16.004/10/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.003/28/2025TPSTTempest TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$169.00 ➝ $91.003/28/2025TPSTTempest TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$611.00 ➝ $208.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookTPSTTempest TherapeuticsN/AN/AN/AN/A$1.39 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateTPSTTempest Therapeutics-$29.49M-$19.51N/AN/AN/AN/A-187.44%-82.61%5/8/2025 (Estimated)Latest TPST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025TPSTTempest Therapeutics-$0.31N/AN/AN/AN/AN/A3/27/2025Q4 2024TPSTTempest Therapeutics-$3.12-$4.03-$0.91-$0.31N/A$0.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthTPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioTPSTTempest TherapeuticsN/A1.691.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipTPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipTPSTTempest Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableTPSTTempest Therapeutics203.52 million41.59 millionOptionableTPST HeadlinesRecent News About These CompaniesTempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual MeetingApril 28 at 4:16 PM | globenewswire.comDual EP2/EP4 Antagonist Designated Orphan Drug for Familial Adenomatous PolyposisApril 25, 2025 | empr.comCash-strapped Bay Area biotech company lays off all but 5 employeesApril 24, 2025 | msn.comTempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-1495April 23, 2025 | nasdaq.comTempest Therapeutics Receives FDA Orphan Drug Designation for TPST-1495 to Treat Familial Adenomatous PolyposisApril 23, 2025 | nasdaq.comTempest TherapeuticsApril 22, 2025 | thepharmaletter.comTempest Therapeutics stock rises on FDA Orphan Drug DesignationApril 21, 2025 | in.investing.comTempest lays off 80% of workforce to ride out cash crunchApril 21, 2025 | fiercebiotech.comTempest Therapeutics announces FDA granted ODD to TPST-1495April 21, 2025 | markets.businessinsider.comTempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAPApril 21, 2025 | globenewswire.comScotiabank Reiterates Sector Perform Rating for Tempest Therapeutics (NASDAQ:TPST)April 12, 2025 | marketbeat.comHC Wainwright Reiterates "Neutral" Rating for Tempest Therapeutics (NASDAQ:TPST)April 12, 2025 | marketbeat.comScotiabank Downgrades Tempest Therapeutics (TPST)April 11, 2025 | msn.comTempest Therapeutics downgraded to Sector Perform from Outperform at ScotiabankApril 10, 2025 | markets.businessinsider.comTempest Therapeutics downgraded to Neutral from Buy at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comTempest hits funding block for Phase III liver cancer drug-in-waitingApril 10, 2025 | finance.yahoo.comTempest, weathering stormy capital markets, hunts for partners for liver cancer drugApril 10, 2025 | fiercebiotech.comTempest to explore alternatives to advance promising pipelineApril 10, 2025 | thepharmaletter.comTempest Therapeutics downgraded at Scotiabank as amezalpat finds no suitorsApril 10, 2025 | markets.businessinsider.comTPST to Evaluate Strategic Options for Pipeline Studies, Stock UpApril 10, 2025 | zacks.comTempest Therapeutics to explore strategic alternativesApril 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTPST Company DescriptionsTempest Therapeutics NASDAQ:TPST$7.16 +0.05 (+0.63%) As of 09:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hershey Hits the Sweet Spot for Defensive Investors AMD Stock Signals Strong Buy Ahead of Earnings Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
